- Balicatib
-
- $56.00 / 5mg
-
2026-04-22
- CAS:354813-19-7
- Min. Order:
- Purity: 98.00%
- Supply Ability: 10g
- Balicatib
-
- $15.00 / 1KG
-
2021-07-13
- CAS:354813-19-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Balicatib
-
- $15.00 / 1KG
-
2021-07-10
- CAS:354813-19-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Balicatib Basic information |
| Product Name: | Balicatib | | Synonyms: | Balicatib;Balicatib, AAE-581;N-(1-(CYANOMETHYLCARBAMOYL)CYCLOHEXYL)-4-(4-PROPYLPIPERAZIN-1-YL)BENZAMIDE;AAE-581;Balicatib N-[1-(Cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide;N-[1-(Cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide Balicatib(AAE-581);Balicatib, >=98%;AAE581; AAE 581; AAE-581 | | CAS: | 354813-19-7 | | MF: | C23H33N5O2 | | MW: | 411.54 | | EINECS: | 200-256-5 | | Product Categories: | Inhibitors | | Mol File: | 354813-19-7.mol |  |
| | Balicatib Chemical Properties |
| Boiling point | 687.4±55.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:52.04(Max Conc. mg/mL);126.45(Max Conc. mM) DMF:25.0(Max Conc. mg/mL);60.75(Max Conc. mM) DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.21(Max Conc. mM) Ethanol:1.75(Max Conc. mg/mL);4.25(Max Conc. mM) | | form | A crystalline solid | | pka | 13.23±0.20(Predicted) | | color | White to off-white | | InChI | InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29) | | InChIKey | LLCRBOWRJOUJAE-UHFFFAOYSA-N | | SMILES | C(NC1(C(NCC#N)=O)CCCCC1)(=O)C1=CC=C(N2CCN(CCC)CC2)C=C1 |
| | Balicatib Usage And Synthesis |
| Uses | Balicatib is a potent inhibitor of Cathepsin K (Cat K), a lysosomal cysteine protease, for the treatment of osteoporosis. | | in vivo | Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys[1]. | Animal Model: | 11-13 years, female cynomolgus monkeys (Macaca fascicularis)[1] | | Dosage: | 0, 3, 10, 50 mg/kg | | Administration: | Oral gavage; twice daily for 18 months | | Result: | Completely prevented ovariectomy-induced increases in BFR/BS in cancellous bone of vertebra and femur and in osteonal and endocortical bone of vertebra, significantly decreased bone formation rates. |
| | IC 50 | cathepsin K: 22 nM (IC50); cathepsin L: 48 nM (IC50); Cathepsin B: 61 nM (IC50); cathepsin S: 2900 nM (IC50) | | storage | Store at -20°C |
| | Balicatib Preparation Products And Raw materials |
|